SPRING BK PHARMACEUTICALS IN's ticker is SBPH and the CUSIP is 849431101. A total of 52 filers reported holding SPRING BK PHARMACEUTICALS IN in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $294,000 | +58.1% | 200,000 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $186,000 | -41.1% | 200,000 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $316,000 | -54.1% | 200,000 | 0.0% | 0.00% | -60.0% |
| Q3 2019 | $688,000 | -6.8% | 200,000 | 0.0% | 0.01% | 0.0% |
| Q2 2019 | $738,000 | -64.8% | 200,000 | 0.0% | 0.01% | -64.3% |
| Q1 2019 | $2,098,000 | +1.0% | 200,000 | 0.0% | 0.03% | -6.7% |
| Q4 2018 | $2,078,000 | -13.8% | 200,000 | 0.0% | 0.03% | +15.4% |
| Q3 2018 | $2,410,000 | -21.7% | 200,000 | -22.9% | 0.03% | -3.7% |
| Q2 2018 | $3,076,000 | -51.7% | 259,536 | -37.3% | 0.03% | -48.1% |
| Q1 2018 | $6,366,000 | +11.0% | 413,916 | -3.0% | 0.05% | +15.6% |
| Q4 2017 | $5,735,000 | -40.0% | 426,682 | -24.9% | 0.04% | -36.6% |
| Q3 2017 | $9,563,000 | +18.1% | 567,871 | -5.0% | 0.07% | +4.4% |
| Q2 2017 | $8,095,000 | +158.1% | 597,879 | +69.7% | 0.07% | +172.0% |
| Q1 2017 | $3,136,000 | -1.9% | 352,361 | -11.9% | 0.02% | -3.8% |
| Q4 2016 | $3,196,000 | – | 400,000 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 941,171 | $1,384,000 | 0.08% |
| EXANE DERIVATIVES | 81,600 | $119,944,000 | 0.03% |
| TIEDEMANN ADVISORS, LLC | 363,114 | $533,000 | 0.03% |
| Private Capital Advisors, Inc. | 52,335 | $77,000 | 0.02% |
| Pegasus Asset Management, Inc. | 18,750 | $28,000 | 0.02% |
| PARSONS CAPITAL MANAGEMENT INC/RI | 59,905 | $88,000 | 0.01% |
| Lee Financial Co | 18,750 | $28,000 | 0.01% |
| ARCADIA INVESTMENT MANAGEMENT CORP/MI | 12,000 | $18,000 | 0.00% |
| Alyeska Investment Group, L.P. | 200,000 | $294,000 | 0.00% |
| Renaissance Technologies | 472,530 | $695,000 | 0.00% |